Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999

Drug Information Journal

Volumn 35, Issue 1, 2001, Pages 293-317

  Fung, M ^a   Thornton, A ^a   Mybeck, K ^a   Wu, J H H ^a   Hornbuckle, K ^a   Muniz, E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Adverse drug reactions; Market discontinuation; Market withdrawal; Postmarketing surveillance

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; VASODILATOR AGENT;

BLOOD TOXICITY; CARCINOGENESIS; CARDIOTOXICITY; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; LIVER TOXICITY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY;

EID: 0035092543     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150103500134     Document Type: Review

References (165)

1. An overview of prescription drug misuse and abuse: Defining the problem and seeking solutions
2. Dependence, abuse and misuse of drugs: Knowledge and attitudes of private physicians in the Ile-de-France
3. Adverse interaction of herbal medicine with breast cancer treatment
4. Monitoring the safety of medicine
5. Post-Marketing surveillance
6. National adverse drug reaction surveillance
7. Management of ADR reports at the FDA
8. Worldwide regulations for manufacturers on clinical safety surveillance of drugs
9. Survey of spontaneous adverse drug reaction reporting schemes in fifteen countries
10. Features of the French postmarketing drug surveillance system. Application to cutaneous effects of nonsteroidal antiinflammatory drugs
11. An evaluation of spontaneous adverse drug reaction monitoring systems
12. Spontaneous adverse drug reaction reporting vs. event monitoring: A comparison
13. Managing adverse reaction information
14. A drug information-ADR collection network: The French system
15. Management of ADR data from different sources
16. International aspects of spontaneous reporting of adverse drug reactions
17. Spontaneous reporting of adverse drug reactions I-II: The data and uses
18. Contraceptive choices - Turning back the clock
19. Increased seizure frequency associated with felbamate withdrawal in adults
20. Is my antihistamine safe?
21. Drugs: 10 Years of recall from the market
22. Pharmacists' liability into the year 2000
23. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin
24. Is the FDA approving drugs too fast? Probably not - But drug recalls have sparked debate
25. When is a drug 'safe'?
26. New active substances authorized in the United Kingdom between 1972 and 1994
27. Drug withdrawals - Circumstances and market impact
28. An analysis of drug recalls and court actions in the United States Pharmaceutical Industry
29. 1996 product withdrawals in France
30. Rate of drug recalls rises sharply - FDA "fast track" approval called into question
31. Drug innovation - What's slowing it down?
32. The role of evidence in the approval of pharmaceuticals
33. Drugs that wouldn't die
34. Drug discontinuation in the United Kingdom and Untied States, 1964 to 1983: Issues of safety
35. The effect of long-term treatment with clozapine in schizophrenia: In 96 patients treated with clozapine for up to 13 years
36. Felbamate
37. New drugs for persons with epilepsy
38. BGA wants molsidomine suspension
39. Problems raised by the withdrawal from the market of drugs in therapeutic use
40. Withdrawal of nifedipine capsules: Jeopardizing the treatment of acute severe hypertension in pregnancy?
41. Prescribe reviews French 1996 launches
42. New drugs: Their market life and safety
43. Alpidem suspended in France
44. Amineptine: Marketing authorization suspended - Drug abuse and dependence, France
45. Effect of regulatory withdrawal of drugs and prescription recommendations on the pattern of self-poisonings in Oslo
46. J&J antihistamine withdrawn. Hismanal taken off shelves
47. Maker to discontinue allergy drug hismanal
48. Astemizole prescription only in UK
49. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective
50. Evaluation of the efficacy and safety of NSAIDs. A new methodological approach
51. The safety of newly approved medicines. Do recent market removals mean there is a problem?
52. A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis
53. Bromfenac sodium capsules (DURACT®) withdrawn from the market
54. Bromfenac (DuractR) withdrawn from the market - Severe liver failure
55. Bromfenac withdrawn - Hepatotoxicity, Saudi Arabia
56. EC chlormezanone withdrawal confirmed
57. Chlormezanone withdrawn because of cutaneous toxicity - Update
58. Chlormezanone marketing authorization withdrawn, Germany
59. Chlormezanone withdrawn, United Arab Emirates
60. Chlormezanone withdrawn, Zimbabwe
61. Chlormezanone withdrawn, Saudi Arabia
62. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, Nov. 1997
63. Warning not to use products containing fenfluramine (Ponderal, Ponderax) or dexfenfluramine (Redux)
64. Withdrawal of fenfluramine (Ponderax) and dexfenfluramine (Adifax)
65. Fenfluramine and dexfenfluramine
66. Fenfluramine and dexfenfluramine. Information for Health Professionals
67. Fenfluramine and dexfenfluramine withdrawn - Cardiotoxicity (USA)
68. Fenfluramine and dexfenfluramine withdrawn, India
69. Fenfluramine and dexfenfluramine: Withdrawn, Saudi Arabia
70. Diet drugs pulled off the market
71. Withdrawal of oxyphenisatin acetate, diacetoxydiphenolisatin and triacetyldiphenolisatin from the Australian market
72. Recall of metamizole from the market in countries with modern pharmacotherapy
73. Metamizole sodium - Prohibited, Nepal
74. Metamizole sodium - Withdrawn due to agranulocytosis, Zimbabwe
75. Metamizole sodium - Withdrawn due to agranulocytosis, Yemen
76. Metamizole sodium - Marketing authorization suspended, Sweden
77. Withdrawal of medicinal products containing ebrotidine - Liver toxicity
78. Bristol-Myers Squibb (BMS) Enkaid withdrawn in US
79. Fenfluramine - Withdrawn
80. Withdrawal of fenoterol and the end of the New Zealand asthma mortality epidemic
81. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: Case-control study
82. Glaxo pulls antibiotic on safety fears
83. The risk-benefit assessment of antidepressant drugs
84. Ketorolac withdrawn in France
85. Ketorolac post marketing surveillance (PMS) study published
86. Ketorolac - Extension of suspension
87. Mianserin agranulocytosis followed by oxitriptan eosinophilia
88. Posicor
89. Mibefradil (Posicor). Information for Health Professionals
90. Mibefradil (Posicor) - Withdrawn from the market: Potential harmful interactions
91. Roche withdraws hypertension drug from the market
92. Mebefradil - Suspended, Germany
93. Muzolimine withdrawn in Europe
94. Ciba-Geigy implements Coramine withdrawal
95. CSM Update. Withdrawal of Nomifensine
96. Immune haemolytic anemia and nomifensine treatment in north west England 1984-85, report of six cases
97. Oxyphenisatin, a laxative responsible for chronic hepatitis and cirrhosis, still marketed in France
98. Liver complications result in withdrawal of attention deficit hyperactivity disorder drug cylert
99. Volital (pemoline) has been withdrawn
100. Pemoline withdrawn - Hepatotoxicity, UK
101. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality
102. The analgesic problem in the Federal Republic of Germany: Analgesic consumption, frequency of analgesic nephropathy and regional differences
103. Phenformin-induced lactic acidosis: A forgotten adverse drug reaction
104. Malaysia withdraws prenylamine registrations
105. Proxibarbal: Voluntary withdrawal
106. UK suspends Lundbeck'S antipsychotic treatment
107. Notification of suspension of Serdolect (sertindole)
108. Suspension of availability of sertindole
109. Sertindole (Serdolect) suspended cardiac arrhythmias and sudden cardiac death
110. Sorivudine & nevirapine on FDA panel
111. Postmarketing surveillance of quinolones, 1990 to 1992
112. Temafloxacin-anatomy of a withdrawal
113. Hoechst Marion Roussel (HMR) withdraws Seldane in US
114. Terfenadine suspension & restricted use
115. Terfenadine prohibited
116. Terfenadine withdrawn - Cardiotoxicity, Saudi Arabia
117. Polymorph ventricular tachycardia with torsades de pointes caused by administration of terodiline (Mictrol)
118. Quality criteria for early signals of possible adverse drug reactions
119. Renal and single-nephron function is comparable in thiobutabarbitone- and thiopentone-anaesthetised rats
120. Ticrynafen's withdrawal from the market
121. Anatomy of drug withdrawals in the United States
122. New chemical entities 1972-1982: Licensing and subsequent adverse reactions. A UK/US comparison
123. Liver complications reported with anti-Parkinson's drug Tasmar
124. Notification of withdrawal of Tasmar
125. Withdrawal of Tasmar (tolcapone) from the market
126. Recommendation for the suspension of the marketing authorization for Tasmar
127. Tolcapone (Tamar) - Liver failure: Suspension & warnings
128. Tolcapone withdrawn - Hepatotoxicity, Australia
129. Tolrestat withdrawn - Hepatic necrosis
130. The Halcion affair in 1979, a false alarm?
131. Secondary effects of drugs. The 1979 Halcion experience in the Netherlands, a false alarm?
132. Withdrawal of triazolam's product licence: Effect on patients 18 months later
133. Medicine and the law. Triazolam suspended
134. Trovafloxacin & alatrofloxacin - Suspension and warnings: Hepatotoxicity
135. Trovafloxacin & alatrofloxacin - Suspension and warnings
136. Diabetes drug spurs worries about safety
137. Troglitazone (Romozin) withdrawn
138. Withdrawal of a drug from the market. What should the prescriber do?
139. Anaphylactic reaction due to zomepirac
140. Comparison of the safety of several nonsteroidal anti-inflammatory drugs currently or formerly marketed in the United Kingdom
141. Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance
142. When should the clinician suspect a drug-induced blood dyscrasia, and how should he proceed?
143. Annual adverse drug experience report: 1995
144. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes
145. Drug and diet interactions: Avoiding therapeutic paralysis
146. Thalidomide: A surprising recovery
147. Thalidomide: Rationale for renewed use in immunological disorders
148. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
149. How to ensure fetal safety when mothers use isotretinoin (Accutane)
150. Electronic transmission of rapid alerts in pharmacovigilance: A pilot EC experiment
151. Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan
152. Limitations of a voluntary reporting system
153. Spontaneous reporting sequences and the Weber effect: A new look at an old phenomenon
154. Analysis of the occurrence of Weber effect in spontaneous adverse event reporting
155. Understanding comparisons of drug introductions between the United States and the United Kingdom
156. Safety considerations in product development
157. FDA panel recommends continued use of controversial diabetes drug
158. FDA places stricter controls on diabetes drug
159. New concerns about side effects of AIDS - Fighting protease inhibitors
160. HIV protease inhibitors - Hyperglycemia
161. HIV protease inhibitors revised data sheet-increased blood sugar
162. HIV protease inhibitors: Lipodystrophy, hyperglycaemia, and nephrolithasis
163. Examining product risk in context. Market withdrawal of zomepirac as a case study